[HTML][HTML] Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
B Gallwitz - Frontiers in Endocrinology, 2022 - frontiersin.org
Incretin-based therapies with glucagon-like peptide-1 receptor agonists (GLP-1RA) are
already established in the treatment of type 2 diabetes (T2D). The development of novel …
already established in the treatment of type 2 diabetes (T2D). The development of novel …
[HTML][HTML] Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
B Gallwitz - Frontiers in Endocrinology, 2022 - ncbi.nlm.nih.gov
Incretin-based therapies with glucagon-like peptide-1 receptor agonists (GLP-1RA) are
already established in the treatment of type 2 diabetes (T2D). The development of novel …
already established in the treatment of type 2 diabetes (T2D). The development of novel …
Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity.
B Gallwitz - Frontiers in Endocrinology, 2022 - europepmc.org
Incretin-based therapies with glucagon-like peptide-1 receptor agonists (GLP-1RA) are
already established in the treatment of type 2 diabetes (T2D). The development of novel …
already established in the treatment of type 2 diabetes (T2D). The development of novel …
[PDF][PDF] Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
B Gallwitz - depression, 2022 - sochob.cl
Recent data from the International Diabetes Foundation (IDF) Diabetes World Atlas released
at the end of 2021 shows a consistently rising prevalence of type 2 diabetes (T2D) with …
at the end of 2021 shows a consistently rising prevalence of type 2 diabetes (T2D) with …
[引用][C] Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
B Gallwitz - Frontiers in Endocrinology, 2022 - tobias-lib.ub.uni-tuebingen.de
Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment
of type-2 diabetes and obesity Clinical perspectives on the use of the GIP/GLP-1 receptor …
of type-2 diabetes and obesity Clinical perspectives on the use of the GIP/GLP-1 receptor …
Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
B Gallwitz - Frontiers in endocrinology, 2022 - pubmed.ncbi.nlm.nih.gov
Incretin-based therapies with glucagon-like peptide-1 receptor agonists (GLP-1RA) are
already established in the treatment of type 2 diabetes (T2D). The development of novel …
already established in the treatment of type 2 diabetes (T2D). The development of novel …
[引用][C] Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
B Gallwitz - Frontiers in Endocrinology, 2022 - ub01.uni-tuebingen.de
Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment
of type-2 diabetes and obesity Clinical perspectives on the use of the GIP/GLP-1 receptor …
of type-2 diabetes and obesity Clinical perspectives on the use of the GIP/GLP-1 receptor …
Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
Frontiers in Endocrinology, 2022 - europepmc.org
Incretin-based therapies with glucagon-like peptide-1 receptor agonists (GLP-1RA) are
already established in the treatment of type 2 diabetes (T2D). The development of novel …
already established in the treatment of type 2 diabetes (T2D). The development of novel …